Double-blind, randomized, multicenter study of doxacurium vs. pancuronium in intensive care unit patients who require neuromuscular-blocking agents

M. J. Murray, D. B. Coursin, P. E. Scuderi, G. Kamath, Donald Prough, D. M. Howard, M. A. Abou-Donia

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Objective: To compare the neuromuscular-blocking and hemodynamic effects of doxacurium vs. pancuronium administered by intermittent bolus to intensive care unit (ICU) patients who required neuromuscular block to facilitate mechanical ventilation for ≥24 hrs. Design: A multicenter, prospective, double-blind, randomized study comparing doxacurium, a new benzylisoquinolone neuromuscular-blocking agent, with pancuronium. Setting: ICUs of three tertiary care hospitals. Patients: Forty critically ill patients (29 male, 11 female) with an average age of 52.5 yrs (range 19 to 80). Interventions: With approval of our Institutional Review Boards and after obtaining informed consent, 40 critically ill patients were entered into the study. Histories and the results of physical examinations were recorded, laboratory data were collected, and Acute Physiology and Chronic Health Evaluation (APACHE) II scores were calculated during the 8 hrs before the start of the study medication. Patients received either doxacurium (initial dose of 0.04 mg/kg) or pancuronium (initial dose of 0.07 mg/kg) by bolus injection with continuous measurement of vital signs every minute for 15 mins. We measured the degree of neuromuscular blockade using a peripheral-nerve stimulator to measure the Train-of-Four count. Patients were rebolused (doxacurium dose of 0.025 mg/kg, pancuronium dose of 0.05 mg/kg) based on clinical criteria, which were substantiated by measurement of the Train-of-Four count. The neuromuscular-blocking drugs were stopped when the patient no longer required paralysis or after 5 days of therapy, whichever came first. Group comparisons were made using repeated measures analysis of variance, Fisher's exact test, and two sample t-tests, when appropriate. Spearman's rank-correlation coefficients were calculated to assess the relationship of onset time and recovery time with all baseline laboratory values and the APACHE II scores. Ap < .05 was used to establish statistical significance. Measurements and Main Results: There were no differences between the two groups with respect to age, gender, or APACHE II scores. There were no differences between groups in terms of adverse experiences, nor with respect to time of onset of block, number of doses, or the duration of neuromuscular blockade (2.6 vs. 2.2 days for doxacurium vs. pancuronium, respectively). There was a statistically significant increase in heart rate after the initial dose of pancuronium (120 ± 23 vs. 109 ± 22 beats/min postinjection vs. preinjection, respectively; p < .05) without any differences noted after doxacurium (107 ± 21 vs. 109 ± 21 beats/min, respectively). Furthermore, once neuromuscular block was discontinued, the pancuronium group had a more prolonged and variable recovery time (279 ± 229 mins) compared with the doxacurium group (138 ± 46 mins, p < .05). Conclusions: In critically ill patients requiring neuromuscular block for >24 hrs, doxacurium was well tolerated without evidence of tachycardia and with a relatively prompt recovery profile.

Original languageEnglish (US)
Pages (from-to)450-458
Number of pages9
JournalCritical Care Medicine
Volume23
Issue number3
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Neuromuscular Blocking Agents
Pancuronium
Multicenter Studies
Intensive Care Units
Neuromuscular Blockade
APACHE
Critical Illness
Vital Signs
Research Ethics Committees
Tertiary Healthcare
Nonparametric Statistics
doxacurium
Informed Consent
Peripheral Nerves
Artificial Respiration
Double-Blind Method
Tertiary Care Centers
Tachycardia
Paralysis
Physical Examination

Keywords

  • critical illness
  • doxacurium
  • drug therapy
  • intensive care unit
  • muscle relaxants
  • neurologic emergencies
  • neuromuscular-blocking agents
  • pancuronium
  • paralytic agents
  • severity of illness index

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Double-blind, randomized, multicenter study of doxacurium vs. pancuronium in intensive care unit patients who require neuromuscular-blocking agents. / Murray, M. J.; Coursin, D. B.; Scuderi, P. E.; Kamath, G.; Prough, Donald; Howard, D. M.; Abou-Donia, M. A.

In: Critical Care Medicine, Vol. 23, No. 3, 1995, p. 450-458.

Research output: Contribution to journalArticle

Murray, M. J. ; Coursin, D. B. ; Scuderi, P. E. ; Kamath, G. ; Prough, Donald ; Howard, D. M. ; Abou-Donia, M. A. / Double-blind, randomized, multicenter study of doxacurium vs. pancuronium in intensive care unit patients who require neuromuscular-blocking agents. In: Critical Care Medicine. 1995 ; Vol. 23, No. 3. pp. 450-458.
@article{abb97526c2b34efbae4f472b6293d3fe,
title = "Double-blind, randomized, multicenter study of doxacurium vs. pancuronium in intensive care unit patients who require neuromuscular-blocking agents",
abstract = "Objective: To compare the neuromuscular-blocking and hemodynamic effects of doxacurium vs. pancuronium administered by intermittent bolus to intensive care unit (ICU) patients who required neuromuscular block to facilitate mechanical ventilation for ≥24 hrs. Design: A multicenter, prospective, double-blind, randomized study comparing doxacurium, a new benzylisoquinolone neuromuscular-blocking agent, with pancuronium. Setting: ICUs of three tertiary care hospitals. Patients: Forty critically ill patients (29 male, 11 female) with an average age of 52.5 yrs (range 19 to 80). Interventions: With approval of our Institutional Review Boards and after obtaining informed consent, 40 critically ill patients were entered into the study. Histories and the results of physical examinations were recorded, laboratory data were collected, and Acute Physiology and Chronic Health Evaluation (APACHE) II scores were calculated during the 8 hrs before the start of the study medication. Patients received either doxacurium (initial dose of 0.04 mg/kg) or pancuronium (initial dose of 0.07 mg/kg) by bolus injection with continuous measurement of vital signs every minute for 15 mins. We measured the degree of neuromuscular blockade using a peripheral-nerve stimulator to measure the Train-of-Four count. Patients were rebolused (doxacurium dose of 0.025 mg/kg, pancuronium dose of 0.05 mg/kg) based on clinical criteria, which were substantiated by measurement of the Train-of-Four count. The neuromuscular-blocking drugs were stopped when the patient no longer required paralysis or after 5 days of therapy, whichever came first. Group comparisons were made using repeated measures analysis of variance, Fisher's exact test, and two sample t-tests, when appropriate. Spearman's rank-correlation coefficients were calculated to assess the relationship of onset time and recovery time with all baseline laboratory values and the APACHE II scores. Ap < .05 was used to establish statistical significance. Measurements and Main Results: There were no differences between the two groups with respect to age, gender, or APACHE II scores. There were no differences between groups in terms of adverse experiences, nor with respect to time of onset of block, number of doses, or the duration of neuromuscular blockade (2.6 vs. 2.2 days for doxacurium vs. pancuronium, respectively). There was a statistically significant increase in heart rate after the initial dose of pancuronium (120 ± 23 vs. 109 ± 22 beats/min postinjection vs. preinjection, respectively; p < .05) without any differences noted after doxacurium (107 ± 21 vs. 109 ± 21 beats/min, respectively). Furthermore, once neuromuscular block was discontinued, the pancuronium group had a more prolonged and variable recovery time (279 ± 229 mins) compared with the doxacurium group (138 ± 46 mins, p < .05). Conclusions: In critically ill patients requiring neuromuscular block for >24 hrs, doxacurium was well tolerated without evidence of tachycardia and with a relatively prompt recovery profile.",
keywords = "critical illness, doxacurium, drug therapy, intensive care unit, muscle relaxants, neurologic emergencies, neuromuscular-blocking agents, pancuronium, paralytic agents, severity of illness index",
author = "Murray, {M. J.} and Coursin, {D. B.} and Scuderi, {P. E.} and G. Kamath and Donald Prough and Howard, {D. M.} and Abou-Donia, {M. A.}",
year = "1995",
doi = "10.1097/00003246-199503000-00007",
language = "English (US)",
volume = "23",
pages = "450--458",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Double-blind, randomized, multicenter study of doxacurium vs. pancuronium in intensive care unit patients who require neuromuscular-blocking agents

AU - Murray, M. J.

AU - Coursin, D. B.

AU - Scuderi, P. E.

AU - Kamath, G.

AU - Prough, Donald

AU - Howard, D. M.

AU - Abou-Donia, M. A.

PY - 1995

Y1 - 1995

N2 - Objective: To compare the neuromuscular-blocking and hemodynamic effects of doxacurium vs. pancuronium administered by intermittent bolus to intensive care unit (ICU) patients who required neuromuscular block to facilitate mechanical ventilation for ≥24 hrs. Design: A multicenter, prospective, double-blind, randomized study comparing doxacurium, a new benzylisoquinolone neuromuscular-blocking agent, with pancuronium. Setting: ICUs of three tertiary care hospitals. Patients: Forty critically ill patients (29 male, 11 female) with an average age of 52.5 yrs (range 19 to 80). Interventions: With approval of our Institutional Review Boards and after obtaining informed consent, 40 critically ill patients were entered into the study. Histories and the results of physical examinations were recorded, laboratory data were collected, and Acute Physiology and Chronic Health Evaluation (APACHE) II scores were calculated during the 8 hrs before the start of the study medication. Patients received either doxacurium (initial dose of 0.04 mg/kg) or pancuronium (initial dose of 0.07 mg/kg) by bolus injection with continuous measurement of vital signs every minute for 15 mins. We measured the degree of neuromuscular blockade using a peripheral-nerve stimulator to measure the Train-of-Four count. Patients were rebolused (doxacurium dose of 0.025 mg/kg, pancuronium dose of 0.05 mg/kg) based on clinical criteria, which were substantiated by measurement of the Train-of-Four count. The neuromuscular-blocking drugs were stopped when the patient no longer required paralysis or after 5 days of therapy, whichever came first. Group comparisons were made using repeated measures analysis of variance, Fisher's exact test, and two sample t-tests, when appropriate. Spearman's rank-correlation coefficients were calculated to assess the relationship of onset time and recovery time with all baseline laboratory values and the APACHE II scores. Ap < .05 was used to establish statistical significance. Measurements and Main Results: There were no differences between the two groups with respect to age, gender, or APACHE II scores. There were no differences between groups in terms of adverse experiences, nor with respect to time of onset of block, number of doses, or the duration of neuromuscular blockade (2.6 vs. 2.2 days for doxacurium vs. pancuronium, respectively). There was a statistically significant increase in heart rate after the initial dose of pancuronium (120 ± 23 vs. 109 ± 22 beats/min postinjection vs. preinjection, respectively; p < .05) without any differences noted after doxacurium (107 ± 21 vs. 109 ± 21 beats/min, respectively). Furthermore, once neuromuscular block was discontinued, the pancuronium group had a more prolonged and variable recovery time (279 ± 229 mins) compared with the doxacurium group (138 ± 46 mins, p < .05). Conclusions: In critically ill patients requiring neuromuscular block for >24 hrs, doxacurium was well tolerated without evidence of tachycardia and with a relatively prompt recovery profile.

AB - Objective: To compare the neuromuscular-blocking and hemodynamic effects of doxacurium vs. pancuronium administered by intermittent bolus to intensive care unit (ICU) patients who required neuromuscular block to facilitate mechanical ventilation for ≥24 hrs. Design: A multicenter, prospective, double-blind, randomized study comparing doxacurium, a new benzylisoquinolone neuromuscular-blocking agent, with pancuronium. Setting: ICUs of three tertiary care hospitals. Patients: Forty critically ill patients (29 male, 11 female) with an average age of 52.5 yrs (range 19 to 80). Interventions: With approval of our Institutional Review Boards and after obtaining informed consent, 40 critically ill patients were entered into the study. Histories and the results of physical examinations were recorded, laboratory data were collected, and Acute Physiology and Chronic Health Evaluation (APACHE) II scores were calculated during the 8 hrs before the start of the study medication. Patients received either doxacurium (initial dose of 0.04 mg/kg) or pancuronium (initial dose of 0.07 mg/kg) by bolus injection with continuous measurement of vital signs every minute for 15 mins. We measured the degree of neuromuscular blockade using a peripheral-nerve stimulator to measure the Train-of-Four count. Patients were rebolused (doxacurium dose of 0.025 mg/kg, pancuronium dose of 0.05 mg/kg) based on clinical criteria, which were substantiated by measurement of the Train-of-Four count. The neuromuscular-blocking drugs were stopped when the patient no longer required paralysis or after 5 days of therapy, whichever came first. Group comparisons were made using repeated measures analysis of variance, Fisher's exact test, and two sample t-tests, when appropriate. Spearman's rank-correlation coefficients were calculated to assess the relationship of onset time and recovery time with all baseline laboratory values and the APACHE II scores. Ap < .05 was used to establish statistical significance. Measurements and Main Results: There were no differences between the two groups with respect to age, gender, or APACHE II scores. There were no differences between groups in terms of adverse experiences, nor with respect to time of onset of block, number of doses, or the duration of neuromuscular blockade (2.6 vs. 2.2 days for doxacurium vs. pancuronium, respectively). There was a statistically significant increase in heart rate after the initial dose of pancuronium (120 ± 23 vs. 109 ± 22 beats/min postinjection vs. preinjection, respectively; p < .05) without any differences noted after doxacurium (107 ± 21 vs. 109 ± 21 beats/min, respectively). Furthermore, once neuromuscular block was discontinued, the pancuronium group had a more prolonged and variable recovery time (279 ± 229 mins) compared with the doxacurium group (138 ± 46 mins, p < .05). Conclusions: In critically ill patients requiring neuromuscular block for >24 hrs, doxacurium was well tolerated without evidence of tachycardia and with a relatively prompt recovery profile.

KW - critical illness

KW - doxacurium

KW - drug therapy

KW - intensive care unit

KW - muscle relaxants

KW - neurologic emergencies

KW - neuromuscular-blocking agents

KW - pancuronium

KW - paralytic agents

KW - severity of illness index

UR - http://www.scopus.com/inward/record.url?scp=0028958212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028958212&partnerID=8YFLogxK

U2 - 10.1097/00003246-199503000-00007

DO - 10.1097/00003246-199503000-00007

M3 - Article

C2 - 7874894

AN - SCOPUS:0028958212

VL - 23

SP - 450

EP - 458

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 3

ER -